RSLS +500% upside potential according to this analyst

NASDAQ:RSLS   ReShape Lifesciences, Inc.
RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.

On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00.
That is more that 5X from the current price.

Looking forward to read your opinion about it.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.